Serum Albumin and Hepatic Synthetic Function

Albumin is the most abundant plasma protein and is synthesised almost entirely by the liver. Because it reflects the hepatocyte's protein-making capacity, serum albumin — alongside the prothrombin time, which measures clotting factors the liver also makes — is one of the few liver-panel markers that genuinely reports hepatic synthetic function rather than injury or clearance. A falling albumin in chronic liver disease signals loss of functional reserve.

Definition

Serum albumin is the principal plasma protein, synthesised by hepatocytes, that maintains plasma oncotic pressure and binds and transports many ligands; its concentration is used as an index of hepatic synthetic function, with the caveat that several non-hepatic factors also influence it.

Scope

The entry covers the synthesis, functions, and turnover of albumin, why it serves as an index of hepatic synthetic function, and the important non-hepatic factors that also lower serum albumin. It treats albumin as a clinical-biochemistry topic and is not guidance for interpreting an individual's results.

Core questions

• Where and how is albumin synthesised, and what are its main physiological functions?
• Why is albumin used as a marker of hepatic synthetic function?
• What non-hepatic factors lower serum albumin and confound its interpretation?
• How do albumin and prothrombin time complement each other as synthetic-function indices?

Key concepts

• Hepatic synthesis of albumin
• Plasma oncotic (colloid osmotic) pressure
• Ligand binding and transport (including unconjugated bilirubin and drugs)
• Long plasma half-life (~3 weeks)
• Marker of synthetic function versus marker of injury
• Negative acute-phase reactant
• Confounders: inflammation, nutrition, renal and gastrointestinal losses, dilution

Mechanisms

Albumin is synthesised in hepatocytes and secreted into plasma, where it is the dominant contributor to colloid osmotic (oncotic) pressure and acts as a carrier for many endogenous and exogenous ligands, including unconjugated bilirubin, fatty acids, hormones, and numerous drugs. Its plasma half-life is roughly three weeks, so the serum level changes slowly and a low value in chronic liver disease reflects sustained loss of synthetic capacity rather than acute injury. Because synthesis depends on functioning hepatocytes, albumin is grouped with the prothrombin time — which reflects hepatically synthesised clotting factors and responds faster — as a marker of synthetic function. However, albumin is also a negative acute-phase reactant whose synthesis falls in inflammation, and its serum concentration is lowered by malnutrition, renal loss (nephrotic syndrome), gastrointestinal loss, and dilution, so a low albumin is not specific to liver disease.

Clinical relevance

Serum albumin is a standard component of the liver panel and one of its few true indicators of synthetic function. This entry explains what albumin is, how it is made, and why it is used as a synthetic-function marker; it describes how the marker is generated and interpreted at the level of biochemistry and patterns, and is not a basis for diagnosing or treating any individual.

Epidemiology

Low serum albumin (hypoalbuminemia) is frequent in hospitalised and chronically ill people and arises from a combination of reduced synthesis, inflammation, redistribution, and losses; in chronic liver disease a falling albumin tracks loss of functional reserve and contributes to composite prognostic scores.

Evidence & guidelines

Reviews of albumin in chronic liver disease and clinical guidance on liver chemistries describe its role as a synthetic-function marker and the multiple non-hepatic determinants that must be considered when interpreting a low value.

History

Albumin was among the first plasma proteins to be characterised and quantified, and its recognition as a hepatically synthesised protein with a long half-life established its enduring role as an index of the liver's synthetic capacity within the conventional liver panel.

Debates

How specific is serum albumin as a liver-function marker?

Because albumin is also a negative acute-phase reactant and is lowered by inflammation, malnutrition, and renal or gastrointestinal losses, a low level is not specific to impaired hepatic synthesis, and its interpretation requires accounting for these confounders.

Seminal works

• spinella-2015

Frequently asked questions

Why is albumin considered a marker of liver function when most liver tests are not?

Albumin is synthesised by the liver, so its concentration reflects the hepatocyte's protein-making capacity; this contrasts with the aminotransferases and alkaline phosphatase, which reflect injury or cholestasis rather than function.

Does a low albumin always mean liver disease?

No. Albumin is a negative acute-phase reactant and is also lowered by inflammation, malnutrition, dilution, and renal or gastrointestinal protein loss, so a low value must be interpreted alongside these other causes.